Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
Updated by a group of distinguished regulatory experts, this new edition is a must-have handbook for regulatory professionals at all levels.
In light of the COVID-19 pandemic, the RAC Board has elected to offer online testing with live online proctoring this summer.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 13 August 2013 | By Alexander Gaffney, RAC,
If you're the sponsor of a wound care product, you may soon be dealing with a new set of regulatory staff at the US Food and Drug Administration (FDA), the agency announced in the Federal Register on Tuesday.
The 13 August 2013 announcement explains that FDA is "transferring oversight responsibilities for certain wound care products" from the Center for Devices and Radiological Health (CDRH), where some new reside, to the Center for Biologics Evaluation and Research (CBER).
The wound care products in question are specifically those containing live cells. Those products are often used as skin substitutes when treating large wounds, such as burns or ones that might otherwise require skin grafts. The products are in many cases engineered into sheets of skin using bioengineered and other materials (such as fibers, which can act as scaffolding), explaining why FDA once regulated them more closely to medical devices.
However, FDA said it is now of the opinion that it makes more sense to regulate these products as biological entities, which are the purview of CBER (through the Center for Drug Evaluation and Research regulates many monoclonal antibodies).
"FDA believes that as more wound care products containing live cells are developed such consolidation is necessary for both efficient and consistent Agency action," it wrote in its Federal Register notice, released on 13 August 2013.
Affected products are those with the product codes MGR, PBD and OCE. FDA said six approved products will be affected by the move:
Most of the affected products also have a number of supplemental applications, which will also be affected by the Center change.
The new regulating authority will be CBER's Office of Cellular, Tissue and Gene Therapies, FDA explained, and will serve to "consolidate primary responsibility for regulating wound care products containing live cells in CBER."
New contact information will be available sometime in the near future on FDA's website, the agency added.
Tags: wound care, Authority
Regulatory Focus newsletters
All the biggest regulatory news and happenings.